Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
暂无分享,去创建一个
M. Minden | T. Panzarella | S. Kamel‐Reid | M. Sukhai | T. Stockley | A. Schimmer | K. Yee | Vikas Gupta | J. Kennedy | A. Schuh | A. Arruda | Mariam Thomas | H. Sibai | R. Devlin | J. Spiegel | J. Bartoszko | D. Maze | Nancy Siddiq | C. McNamara | J. Ho | Caroline J. McNamara | Jamie Claudio | Rebecca Devlin | Justyna Bartoszko
[1] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[2] A. Tefferi,et al. Targeted deep sequencing in primary myelofibrosis. , 2016, Blood advances.
[3] Vikas Gupta,et al. Myelofibrosis: to transplant or not to transplant? , 2016, Hematology. American Society of Hematology. Education Program.
[4] K. Gregory,et al. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] T. Panzarella,et al. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis. , 2015, Clinical lymphoma, myeloma & leukemia.
[6] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[7] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[8] Francisco Cervantes,et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis , 2015, Haematologica.
[9] M. Griesshammer,et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group , 2015, Leukemia.
[10] H. Kantarjian,et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. , 2015, Blood.
[11] A. Tefferi,et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis , 2014, Leukemia.
[12] M. Cazzola,et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. , 2014, Blood.
[13] P. Guglielmelli,et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients , 2014, Leukemia.
[14] Vikas Gupta,et al. Controversies and dilemmas in allogeneic transplantation for myelofibrosis. , 2014, Best practice & research. Clinical haematology.
[15] Christian Beisel,et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.
[16] M. Cazzola,et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. , 2014, Blood.
[17] T. Barbui,et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.
[18] J. Dipersio,et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I , 2013, Haematologica.
[19] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.
[20] Francisco Cervantes,et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.
[21] J. Dipersio,et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis , 2013, British journal of haematology.
[22] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[23] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[24] M. Cazzola,et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. , 2010, Blood.
[25] M. Cazzola,et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients , 2014, Leukemia.
[26] Elizabeth M. Smigielski,et al. dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..